Le podologue participe à la prévention des chutes des personnes âgées

Effectiveness of a multifaceted podiatry intervention to prevent falls in community dwelling older people with disabling foot pain: randomised controlled trial

OPEN ACCESS

1. Martin J Spink, PhD candidate12,
2. Hylton B Menz, professor1,
3. Mohammad R Fotoohabadi, research officer1,
4. Elin Wee, research officer1,
5. Karl B Landorf, senior lecturer12,
6. Keith D Hill, professor of allied health134,
7. Stephen R Lord, senior principal research fellow56

+ Author Affiliations

1. ¹Musculoskeletal Research Centre, Faculty of Health Sciences, La Trobe University, Bundoora Victoria, Australia
2. ²Department of Podiatry, Faculty of Health Sciences, La Trobe University, Bundoora, Victoria, Australia
3. ³Division of Allied Health, Northern Health, Epping, Victoria, Australia
4. ⁴Preventive and Public Health Division, National Ageing Research Institute, Parkville, Victoria, Australia
5. ⁵School of Public Health and Community Medicine, University of New South Wales (UNSW), Sydney, NSW, Australia
6. ⁶Neuroscience Research Australia, Randwick, Sydney, NSW, Australia

1. Correspondence to: H B Menz h.menz@latrobe.edu.au

• Accepted 18 April 2011

Abstract

Objective To determine the effectiveness of a multifaceted podiatry intervention in preventing falls in community dwelling older people with disabling foot pain.

Design Parallel group randomised controlled trial.

Setting University health sciences clinic in Melbourne, Australia.

Participants 305 community dwelling men and women (mean age 74 (SD 6) years) with disabling foot pain and an increased risk of falling. 153 were allocated to a multifaceted podiatry intervention and 152 to routine podiatry care, with 12 months’ follow-up.

Interventions Multifaceted podiatry intervention consisting of foot orthoses, advice on footwear, subsidy for footwear ($A100 voucher; £65; €74), a home based programme of foot and ankle exercises, a falls prevention education booklet, and routine podiatry care for 12 months. The control group received routine podiatry care for 12 months.

Main outcome measures Proportion of fallers and multiple fallers, falling rate, and injuries resulting from falls during follow-up.

Results Overall, 264 falls occurred during the study. 296 participants returned all 12 calendars: 147 (96%) in the intervention group and 149 (98%) in the control group. Adherence was good, with 52% of the participants completing 75% or more of the requested three exercise sessions weekly, and 55% of those issued orthoses reporting wearing them most of the time. Participants in the intervention group (n=153) experienced 36% fewer falls than participants in the control group (incidence rate ratio 0.64, 95% confidence interval 0.45 to 0.91, P=0.01). The proportion of fallers and multiple fallers did not differ significantly between the groups (relative risk 0.85, 0.66 to 1.08, P=0.19 and 0.63, 0.38 to 1.04, P=0.07). One fracture occurred in the intervention group and seven in the control group (0.14, 0.02 to 1.15, P=0.07). Significant improvements in the intervention group compared with the control group were found for the domains of strength (ankle eversion), range of motion (ankle dorsiflexion and inversion/eversion), and balance (postural sway on the floor when barefoot and maximum balance range wearing shoes).

Conclusions A multifaceted podiatry intervention reduced the rate of falls in community dwelling older people with disabling foot pain. The components of the intervention are inexpensive and relatively simple to implement, suggesting that the programme could be incorporated into routine podiatry practice or multidisciplinary falls prevention clinics.

Trial registration Australian New Zealand Clinical Trials Registry ACTRN12608000065392.

L’AFSSAPS suspend l’AMM de Nizoral

L’Afssaps a décidé de suspendre l’autorisation de mise sur le marché de Nizoral® (kétoconazole) 200 mg, comprimé, dans la prise en charge des infections fongiques (provoquées par un champignon), en raison de sa toxicité pour le foie, plus fréquente et plus sévère qu’avec d’autres traitements antifongiques. Dans l’attente des conclusions de la réévaluation du bénéfice/risque de Nizoral® en tant qu’antifongique engagée au plan européen, l’Afssaps recommande aux patients actuellement traités par ce médicament de consulter leur médecin. Nizoral® restera disponible dans le cadre d’Autorisations Temporaires d’Utilisation (ATU) nominatives délivrées par l’Afssaps pour la prise en charge des patients atteints du syndrome de Cushing

 A LIRE